articleJournal of the American College of CardiologyAug 30, 2024HYBRID OA

Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure

SDScott D. SolomonJWJohn W. OstrominskiXWXiaowen WangSJSanjiv J. ShahBABarry A. Borlaug

Brigham and Women's Hospital · Harvard University · +23 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Obesity is associated with adverse cardiac remodeling and is a key driver for the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) has been shown to improve HF-related symptoms and physical limitations, body weight, and exercise function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), but the effects of semaglutide on cardiac structure and function in this population remain unknown. In this echocardiography substudy of the STEP-HFpEF Program, we evaluated treatment effects of once-weekly semaglutide (2.4 mg) vs placebo on cardiac structure and function. Echocardiography at randomization and 52 weeks was performed in 491 of 1,145…

Citation impact

110
total citations
FWCI
41.83
Percentile
100%
References
57
Citations per year

Authors

24

Topics & keywords

Topics
Keywords
  • Semaglutide
  • Medicine
  • Heart failure
  • Ejection fraction
  • Cardiology
  • Cardiac function curve
  • Internal medicine
  • Obesity
No related works found for this paper.

Funding